# Biotech Pipeline - Gene/Cell, Neuro & Tools - Week of May 31, 2026: Pharma Votes With Its Feet Toward China > Biotech podcast newsletter for May 25–31, 2026. The headline gene/cell, anti-amyloid, and tools tapes were quiet, while the dominant argument was structural: big pharma is licensing its next decade of assets straight out of China, with the Wuxi Biologics / Viridian deal as the real-time tell. ## Biotech Pipeline: Gene/Cell, Neuro & Tools ### Week of May 25–31, 2026 --- ```request-access variant: ghost heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` Hey, a strange week on the pods. The headline names we usually obsess over (Casgevy, the in-vivo editors, Leqembi) were almost invisible. What dominated instead was a much bigger structural argument: big pharma has quietly stopped waiting on Washington, and is licensing its next decade of assets straight out of China. If you own US biotech or the tools that supply it, that's the thread to pull on this week. --- ## TL;DR - The Wuxi Biologics / Viridian manufacturing deal, signed despite BIOSECURE Act overhang, is a real-time tell that the bypass is operational, not theoretical. - Buyside sentiment is now sharply ahead of operators: the Endpoints Q2 finance/investment sub-index jumped +50 points QoQ to 120, and 11 biotech IPOs YTD already match all of 2025. - The gene/cell, anti-amyloid, and tools tapes were essentially quiet this week. Anyone telling you they got a fresh Casgevy or Leqembi data point from a podcast is making it up. --- ## 🆕 What's New **1. The COINS Act / BIOSECURE debate has a new operator on the record, and it's Jason Kelly.** On this week's Biotech Hangout (May 29), Ginkgo Bioworks (DNA) CEO and former chair of the U.S. National Security Commission on Emerging Biotechnology Jason Kelly made the most aggressive public case yet for the COINS Act. His killer stat: 1,100 Massachusetts R&D/discovery scientist jobs lost in 2024, the first decline MassBio has ever tracked, and roughly a third of Massachusetts lab space sitting vacant, both of which he pinned on drug-discovery work being offshored to China. As Kelly put it on the show: > *"70% of the profits for therapeutics originate with U.S. consumers who make up 4% of the world's population… The U.S. voter pays for the profits of the drug industry, period."* He dismissed the RA Capital "euro-washing" workaround (routing China-discovered molecules through Europe before US deals) as "nonsense." The read-through to DNA itself: if COINS passes in anything close to its current form, the synbio platform is suddenly the only at-scale US-soil alternative for a chunk of early-stage discovery work that's been quietly leaving the country. **2. Pfizer just told you what big pharma actually thinks.** On the same Biotech Hangout episode, host Chris Garabedian (former Sarepta CEO) framed the counter-thesis bluntly: the bigger risk isn't China losing US access, it's that pharma simply *bypasses* US biotech entirely. He pointed at Pfizer's recent China licensing deal (following BMS/Hengrui and GSK/Hengrui) and the new Wuxi Biologics manufacturing agreement with Viridian Therapeutics (VRDN), signed *despite* BIOSECURE Act overhang. His punchline: > *"I think the bigger risk is that pharma bypasses U.S. biotech and goes straight to China to do the deals… They don't need U.S. biotech. They don't need the financing behind that."* That is, in one sentence, the bear case for the entire small/mid-cap US biotech complex and a quiet bull case for the Chinese CDMO/discovery stack. Worth re-underwriting any name whose thesis assumes "pharma will buy them out at a premium." **3. The sentiment data has a tell of its own.** Garabedian cited the Q2 2026 Endpoints biopharma sentiment index reading of 96 (up from 90 in Q1 and 78 in Q4 2025) on the same episode. The notable wrinkle: among finance/investment respondents specifically, the current-conditions sub-index jumped +50 points QoQ to 120, the highest of any cohort. Buyside is now meaningfully more bullish than the operator base. Combine that with 11 biotech IPOs YTD already matching/beating full-year 2025, including the Cardigan filing (>$500M raised pre-IPO, three Phase 2b cardiometabolic assets, ex-MyoKardia leadership), and you have a window opening for capital-raising that didn't exist three months ago. As Garabedian noted, "this collection of IPOs is a little bit different, later stage, clinical," which is exactly what you want if the cycle is real. **4. A small but interesting read-through on CNS delivery.** On DNA Today #396 (May 29), Boise State neuroscientist Dr. Troy Rohn, co-founder of private-co Cognigenics, walked through their intranasal siRNA program targeting the 5-HT2A serotonin receptor, with single-dose durability estimated at 6–12 months and an explicit argument that reversible siRNA, not permanent CRISPR, is the more investable modality for CNS: > *"When you talk about mental health, that makes the FDA very nervous. It makes investors nervous."* Not a name in itself, but a useful framing for anyone trying to handicap regulatory risk on CNS-directed CRISPR programs (think Beam's CNS strategy, future Verve-style brain work). The intranasal-bypassing-the-blood-brain-barrier angle is also worth filing for the broader CNS delivery debate. --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## ⚖️ The Debate (Mostly One-Sided This Week) The voiced bear case on the tape: **pharma doesn't need US biotech anymore.** China assets are cheaper, faster, and (post-Wuxi/Viridian) apparently still bankable even with BIOSECURE hanging in the wind. Workarounds (euro-washing, manufacturing-only deals, joint licensing structures) are multiplying faster than legislation can keep up. If you're long a clinical-stage US biotech whose exit is "get bought," the path just narrowed. The voiced bull case: **the US is finally waking up.** Kelly's argument is that COINS / BIOSECURE-style measures aren't trade protectionism, they're industrial policy for the only industry where Americans pay the world's drug bill. If that view wins in DC, US-soil platforms (Ginkgo, US-based CDMOs, domestic gene/cell manufacturers) re-rate. In fairness, the gene/cell ramp bull case (faster-than-feared Casgevy throughput, durable in-vivo knockdown data, a SubQ Leqembi inflection, a tools restock) wasn't voiced on the pods this week. That doesn't mean it's wrong, just that no operator or analyst we follow chose to put it on tape in the last seven days. We'll re-engage when they do. --- ## 🎯 Names in Play - **Ginkgo (DNA):** Kelly's appearance is the most overt political-tailwind narrative DNA has had in a year. Catalyst to watch: any COINS Act markup or Senate action. Bear: Kelly is a self-interested narrator; the platform's commercial economics aren't suddenly different. - **Viridian (VRDN):** the Wuxi deal is operationally good (capacity secured) but politically risky if BIOSECURE tightens. Worth checking the deal terms for re-domiciling optionality. - **Pfizer (PFE), BMS, GSK:** the licensors-from-China cohort. Implication: their internal R&D productivity bar for US assets just went up. Less obvious bidder support under any US biotech. - **Cardigan:** IPO to track; ex-MyoKardia team, late-stage cardiometabolic, the kind of name that defines a window. --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 🔁 Read-Throughs - **Wuxi Biologics / Wuxi AppTec:** the Viridian signing is the cleanest "BIOSECURE is leakier than you think" data point of the year so far. - **US-based CDMOs and viral-vector/LNP shops:** political tailwind if COINS gains traction; commercial headwind if pharma keeps routing around them. - **Casgevy ecosystem (CRSP, VRTX), in-vivo editors (NTLA, BEAM, VERV), anti-amyloid (BIIB/Eisai, LLY), tools (TMO, DHR, A, RVTY, Sartorius, Repligen, ILMN, Bruker):** no actionable podcast commentary this week. Not down, not up, quiet. Re-engage on next week's tape and on Q2 prints. --- ## 📌 What Changed Three things, all from Biotech Hangout this week: 1. The Wuxi/Viridian deal is now a public, named example of pharma-side BIOSECURE workaround. It stops being a hypothetical. 2. The Endpoints finance sub-index reading (+50 pts QoQ to 120) is the first hard sentiment number where buyside has decisively decoupled from operators on the upside. 3. The COINS Act now has a high-profile operator-spokesperson in Kelly. Previously the debate was almost entirely Beltway and trade-association. The Casgevy / in-vivo editing / Leqembi narratives didn't change because nobody we follow voiced them. We'll flag the moment they do. --- ## Sources - [Biotech Hangout, Episode 184 - May 29, 2026 (Chris Garabedian, Brian Skorney, Greg Sivanovich, Jason Kelly)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhUNuOXbbCHNTxfMUrt1EmG2CSzlRsf73fmIbtcD90zKr-2BvtGB87wH7t-2FmbfXlzozYsVAWgXDlCWqbLskM8FN7KE-2BZsWfwofCDtLPjipy3L8Q-3D-3DurKt_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7PIqiPfJWXuV5QuGHa7-2FYeAAAn9sCj-2FLoiUznWlWqz55cFbzwQTVd0f6WrhYVq-2FIc51E7n2QqgkG7NTS92nxgLDkDxqJFD8oQsDJQ39axcYE5m0f4JTZAkGHTU9QNn0u0l9x4g7WcMwmT2mjXlmiwDyrnxtI4O6Qn7s9kTjm8WeqjEMzGgqHlqUG9-2FNnKMag-3D) - [DNA Today, Episode #396 - May 29, 2026 (Kira Dineen, Dr. Troy Rohn)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgosuSK7zGMinmdJNtttAKdsyjD9-2FmG7ifZHUYbyElB0OShYZF-2F-2FAjdG1VnJt-2Ff71c8qO-2B485bH9j-2BohcMZDj5y-2F07313wU1vWdECDolcXNeA-3D-3DiOKS_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7PIqiPfJWXuV5QuGHa7-2FYeAAAn9sCj-2FLoiUznWlWqz1VERP4G4pm8idZaRWLKKNj8E7wSmdGY-2FJf-2BzZ0DD-2Fk1FmjFukqOe-2BGfIvBmy-2FFwxHVCXGPaCWc3Fa6sUkSN16pC7TMWbXmZ8O7uVXI28-2Bq4ktJHYe5QTMtDKMfwA7bmwQZi-2FWJqbnrvrc4XkrlrYnI-3D) ```request-access variant: banner heading: Run your own corpus. description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage. buttonText: Request access ```